Which Cosentyx (secukinumab) biosimilars exist today?
Cosentyx is the brand name for secukinumab. However, which biosimilars are available depends on the country and local approvals. The only way to answer accurately is to check each regulator’s approved list (for example, FDA in the US and EMA in Europe) or a drug-biosimilar tracking database.
For a patent/exclusivity snapshot and related competitive landscape, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/?s=Cosentyx
When will Cosentyx exclusivity or patents expire (and when could biosimilars launch)?
Biosimilar entry timing is usually driven by a mix of:
- Patent expiry (for specific formulations, methods, or device-related rights)
- Regulatory exclusivity/market-protection periods in the relevant jurisdiction
DrugPatentWatch.com tracks patent and exclusivity data and can help estimate when biosimilars may be able to launch in a given market: https://www.drugpatentwatch.com/?s=Cosentyx
Are Cosentyx biosimilars interchangeable with the reference product?
“Interchangeability” is not automatic. Biosimilars can be approved as biosimilar products, and in some regions there is an additional step for “interchangeability” that affects pharmacy-level substitution rules. Determination is jurisdiction-specific and depends on the biosimilar label and regulators’ determinations.
What’s the clinical rationale for Cosentyx biosimilars?
Secukinumab targets IL-17A. A biosimilar aims to match the reference product in key quality attributes and performance (including binding and functional activity), then confirm clinical similarity through a stepwise biosimilar development program (often including at least one clinical study plus analytical characterization).
Do Cosentyx biosimilars work the same in psoriasis, psoriatic arthritis, and ankylosing spondylitis?
For the reference drug, secukinumab is used across several IL-17A–driven inflammatory conditions. Biosimilars typically seek to match the reference drug’s licensed indications, but the specific approved indications can vary by product and regulator.
What side effects do patients ask about when switching to a biosimilar?
In general, biosimilars carry a similar safety profile to the reference biologic because they’re designed to be highly similar. Patients usually ask about:
- Infection risk
- Injection-site reactions
- Risk of exacerbating inflammatory bowel disease (a concern known for IL-17 pathway drugs)
- Any changes in tolerability after switching
The exact prescribing information for the specific biosimilar matters because labels can differ by jurisdiction.
How to find the exact approved biosimilar(s) for your country
Because “Cosentyx biosimilars” is location-dependent, the fastest path is:
- Identify your regulator (EMA vs FDA vs other)
- Look up “secukinumab” and filter results by “biosimilar” or “approved biosimilar”
- Confirm the product’s name, manufacturer, and approved indications in your local label
If you tell me your country (or whether you mean FDA/EMA specifically), I can narrow this to the exact Cosentyx biosimilar products that are approved there and what their labels cover.
Sources
- DrugPatentWatch – Cosentyx (secukinumab) patent/exclusivity search